IL23A and psoriasis vulgaris: Ustekinumab is a fully humanized IgG1κ monoclonal antibody (mAb) that inhibits the p40 chain shared by IL-12 and IL-23, which is FDA approved for the treatment of plaque psoriasis and psoriatic arthritis (21).